How does SaiyanMed’s team select premium raw materials? The short answer is: through a multi-layered, source-to-ship verification system that starts with supplier audits, runs through in-house material science evaluations, and ends with independent third-party testing at Janoshik. Every gram of raw material goes through a documented chain of custody before it ever touches a production line.
Let’s break down the actual process. The team doesn’t just buy from the cheapest catalog. Eric, the founder, holds a Bachelor’s degree in Materials Science from a top Chinese university, specializing in biomaterials. That background means the selection criteria are based on real chemistry, not marketing fluff. The raw material sourcing team, led by senior chemists, evaluates suppliers based on five core parameters: purity percentage (targeting ≥99% by HPLC), residual solvent levels (below ICH Q3C limits), heavy metal content (under 10 ppm), endotoxin levels (below 1 EU/mg), and peptide content (actual peptide weight vs. gross weight).
Here’s a concrete example of how they screen incoming raw materials. When a batch of a common research peptide arrives, the team runs a full panel of tests before it’s approved for lyophilization:
| Parameter | Acceptance Threshold | Test Method |
|---|---|---|
| Purity (HPLC) | ≥99.0% | Reverse-phase HPLC with UV detection at 214 nm |
| Peptide Content | 80-90% (by weight) | Amino acid analysis after hydrolysis |
| Residual TFA | <50 ppm | Ion chromatography |
| Heavy Metals | <10 ppm total | ICP-MS |
| Endotoxin | <1 EU/mg | LAL chromogenic assay |
| Water Content | <5% | Karl Fischer titration |
If any single parameter fails, the entire batch is rejected. No exceptions. The team then notifies the supplier and documents the failure in a shared database that tracks supplier performance over time. Suppliers with more than two rejections in a rolling 12-month period are automatically flagged for re-audit. This data-driven approach means the selection process is constantly improving based on real-world results.
The sourcing team also visits manufacturing facilities in person. They inspect cleanroom classifications (targeting ISO Class 7 or better), check the age and calibration of HPLC and mass spectrometry equipment, and review the supplier’s own batch records. They look for things like consistent column performance, proper sample preparation protocols, and whether the supplier runs their own stability studies. A supplier that can’t show a log of daily column pressure checks doesn’t get a contract.
One of the less talked about factors is the raw material’s form. The team prefers lyophilized (freeze-dried) powders over spray-dried or crystallized forms because lyophilization preserves the peptide’s secondary structure and reduces degradation during storage. They test the reconstitution clarity: a clear, particle-free solution after adding sterile water is a good sign; any haze or precipitation means the batch is suspect. They also check the pH of the reconstituted solution, aiming for a range of 4.5 to 6.5, which is typical for most research peptides.
Another layer is the origin of the raw materials. The team tracks the country of origin for each peptide’s starting materials. For example, certain amino acid derivatives used in peptide synthesis are sourced from specific regions known for high-quality production. They maintain a database of preferred suppliers for each key intermediate, so if a supplier changes their source of a raw material, SaiyanMed’s team is notified and can re-evaluate the batch.
The selection process also includes a “blind” testing phase. The team sends samples from a new supplier to Janoshik without revealing the supplier’s identity. Janoshik runs a full analysis, including purity, peptide content, and impurity profiling. The results are compared against the supplier’s own certificate of analysis. If there’s a discrepancy of more than 0.5% in purity, the supplier is required to explain the difference. This blind test is repeated every six months for all active suppliers.
Let’s talk numbers. In 2024, SaiyanMed’s team evaluated 47 potential raw material suppliers. Out of those, only 12 passed the initial screening. After the full audit and blind testing, only 7 were approved as active suppliers. The rest were rejected for reasons ranging from inconsistent purity (one supplier had a batch-to-batch purity variation of 3.2%) to failure to provide complete batch records. The team maintains a rejection rate of about 85% for new suppliers, which is high but intentional. They’d rather have fewer, more reliable sources than a long list of questionable ones.
Once a supplier is approved, the team doesn’t just trust them. Every incoming batch is sampled and tested independently. The sampling protocol follows a strict statistical plan: for batches of 1 kg or less, five random samples are taken; for larger batches, the number of samples increases proportionally. Each sample is tested for purity, peptide content, and endotoxin. If any sample fails, the entire batch is quarantined and retested. If the retest fails, the batch is rejected and returned to the supplier.
The team also uses a technique called “forced degradation” to test the stability of raw materials. They take a small sample and expose it to elevated temperature (40°C) and humidity (75% RH) for 72 hours, then re-test the purity. A good raw material should show less than 1% degradation under these conditions. If the degradation is higher, the material is flagged as potentially unstable and the supplier is asked to provide additional stability data.
Another critical factor is the packaging. The team requires raw materials to be shipped in USP Class VI, double-bagged, vacuum-sealed containers with desiccant and oxygen absorbers. They check the packaging upon arrival and reject any batch where the vacuum seal is broken or the desiccant has changed color. They also log the temperature of the shipment using data loggers. If the temperature exceeded 25°C during transit, the batch is quarantined and tested for degradation before any further processing.
The selection process doesn’t stop at the raw material level. It extends into the production process at SaiyanMed’s own facilities. The team uses a multi-step purification process that includes preparative HPLC, followed by lyophilization. They monitor the lyophilization cycle parameters, including freezing rate, primary drying temperature, and secondary drying time, to ensure the final product matches the raw material’s quality. Every batch’s lyophilization cycle is recorded and compared against the cycle for the raw material’s reference standard. Any deviation of more than 5% in cycle time triggers a review.
All of this is documented in a batch record that includes the raw material’s supplier, batch number, test results, and the lyophilization cycle parameters. These records are kept for at least five years and are available for inspection by researchers upon request. The team also maintains a database of all raw material batches, cross-referenced by supplier, peptide type, and test results. This allows them to quickly identify trends, such as a supplier whose batches are showing a gradual decline in purity over time.
For researchers who want to dig deeper, saiyanmed provides access to each batch’s certificate of analysis from Janoshik, which includes the raw data from the HPLC and mass spectrometry runs. This is not a summary or a pass/fail grade; it’s the actual chromatogram and the mass spectrum, so you can see the impurity profile yourself. The team also publishes the method parameters used for the HPLC analysis, including the column type, mobile phase composition, gradient program, and detection wavelength.
One more detail: the team uses a “reserve sample” system. For every batch of raw material, they keep a 1-gram sample stored in a controlled environment (2-8°C, desiccated, under argon) for at least two years. If a researcher ever has a question about a specific batch, the team can pull the reserve sample and run additional tests. This is not a common practice in the industry, but it’s part of the selection process because it allows for retrospective verification.
Finally, the team’s selection criteria are not static. They review and update the supplier qualification standards every six months based on the latest industry guidelines, including the FDA’s guidance on peptide drug products and the USP’s general chapters on peptide purity. They also incorporate feedback from researchers who use the products. If a researcher reports an unexpected result, the team investigates whether the raw material could be a factor. This feedback loop means the selection process is always evolving based on real-world use.